FY2026 EPS Estimates for Invivyd Increased by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Invivyd to a loss of $0.46 per share from $0.48 and maintained a “Buy” rating. The firm projects profitability beginning in FY2028, reaching estimated EPS of $1.10 by FY2030.
• Invivyd’s latest quarterly results fell short of expectations, with an EPS loss of $0.14 versus the $0.11 consensus and revenue of $14.29 million versus $14.40 million expected. The company continues to report substantial losses and negative margins.
• The stock recently traded near $0.96, while analyst sentiment remains mixed: the consensus rating is “Hold” with an $8.00 average price target. Institutional investors own approximately 70% of shares, while several insiders recently sold stock primarily to cover tax-withholding obligations.

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Invivyd in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.46) per share for the year, up from their previous estimate of ($0.48). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Invivyd's current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for Invivyd's Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.12 EPS, FY2029 earnings at $0.52 EPS and FY2030 earnings at $1.10 EPS.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.

A number of other research firms have also weighed in on IVVD. Wall Street Zen lowered Invivyd from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. BTIG Research restated a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Invivyd in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Invivyd has a consensus rating of "Hold" and an average price target of $8.00.

Invivyd Stock Up 10.3%

Shares of Invivyd stock opened at $0.96 on Thursday. The stock's fifty day moving average is $0.77 and its 200-day moving average is $1.23. The firm has a market capitalization of $282.82 million, a PE ratio of -2.91 and a beta of 0.71. Invivyd has a 12-month low of $0.48 and a 12-month high of $3.07.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently modified their holdings of IVVD. Courier Capital LLC acquired a new position in Invivyd during the fourth quarter valued at $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in Invivyd during the 4th quarter worth about $27,000. DRW Securities LLC acquired a new stake in Invivyd during the 4th quarter worth about $27,000. ProShare Advisors LLC acquired a new stake in Invivyd during the 4th quarter worth about $30,000. Finally, State of Wyoming purchased a new position in Invivyd during the 4th quarter valued at about $30,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Insiders Place Their Bets

In other Invivyd news, insider Jill Andersen sold 37,256 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $26,824.32. Following the sale, the insider directly owned 314,480 shares of the company's stock, valued at $226,425.60. The trade was a 10.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 228,024 shares of company stock worth $176,540. Insiders own 12.25% of the company's stock.

Invivyd News Roundup

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source